About Intera Oncology
Intera Oncology is a Healthcare company based in Wellesley (United States) founded in 2019 by Jonathan Reis, and was acquired by Boston Scientific in November 2024. Hepatic artery infusion therapy is developed for cancer treatment. Intera Oncology offers products and services including Intera 3000 HAI Pump. Its focus areas include Life Sciences, Oncology, Medical Devices and Therapies. Its competitors include TriSalus Life Sciences, Cooler Heads and Delcath; 2 of its 3 listed competitors have raised funding.
Company details
Intera Oncology was founded in 2019 in Wellesley, United States, within the oncology sector. Hepatic artery infusion therapy is developed by the company to address liver metastases from colorectal cancer and cholangiocarcinoma. The Intera 3000 pump, equipped with a beaded catheter, is used to deliver floxuridine directly to the hepatic artery. Operations focus on medical device innovation for targeted cancer therapies in the United States.
- Headquarters Wellesley, United States
- Founders Jonathan Reis
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website interaoncology.com
- Social LinkedIn X Facebook
- Acquired by Boston Scientific (Nov 2024)
- Investors
- Acquired byBoston Scientific
(Nov 2024)
Products & Services of Intera Oncology
Intera Oncology offers a comprehensive portfolio of products and services, including Intera 3000 HAI Pump.
Implantable pump for delivering chemotherapy directly to the liver.
Investors in Intera Oncology
Intera Oncology has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Boston Scientific.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Wide range of medical devices | 1979 | bostonscientific.com | Marlborough, United States |
Investor details for Intera Oncology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Intera Oncology
6 people are tracked at Intera Oncology (4 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Jonathan Reis | Founder | Leadership |
Michael Gaisford | CEO | Leadership |
Julia Yael Adams | Vice President Marketing | Leadership |
Zachary Lappen | Director of Operations and Engineering | Leadership |
David Marshak | Senior Marketing Manager, Product Management And Patient Engagement | Team |
Kari Bechert | Senior Marketing Manager, HCP Programs | Team |
Complete people profiles for Intera Oncology
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Intera Oncology
2 dated milestones of Intera Oncology across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Intera Oncology is founded.
- Exit Acquired by Boston Scientific.
Competitors of Intera Oncology
Intera Oncology has 3 listed competitors in our database, 2 of them funded. They include TriSalus Life Sciences, Cooler Heads and Delcath.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| trisaluslifesci.com | 2009 | Westminster, United States | $83.37M | 100 | Developer of drug delivery devices to treat cancers | |
| coolerheads.com | 1998 | San Diego, United States | $23.11M | Developer of cold cap system to prevent chemotherapy side effects | ||
| delcath.com | 1987 | New York, United States | 52 | Delcath Systems, Inc. is focused on liver cancer treatments. |
Detailed competitors of Intera Oncology
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Intera Oncology
The website of Intera Oncology (interaoncology.com) receives about 3.4K visits a month.
- Monthly visits3.4K
▼ 3.8% vs previous month
Top companies in Oncology
3 companies that operate in the same segment as Intera Oncology (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Intera Oncology
Complete news archive for Intera Oncology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Intera Oncology
Intera Oncology was founded in 2019.
Intera Oncology is headquartered in Wellesley, United States. It is registered at Wellesley, Massachusetts, United States.
Intera Oncology was founded in 2019 in Wellesley, United States, within the oncology sector. Hepatic artery infusion therapy is developed by the company to address liver metastases from colorectal cancer and cholangiocarcinoma. The Intera 3000 pump, equipped with a beaded catheter, is used to deliver floxuridine directly to the hepatic artery. Operations focus on medical device innovation for targeted cancer therapies in the United States.
Intera Oncology's top competitors include TriSalus Life Sciences, Cooler Heads and Delcath.
Intera Oncology offers Intera 3000 HAI Pump.
Intera Oncology has 1 investor. Key investors include Boston Scientific.
Yes. Intera Oncology was acquired by Boston Scientific in November 2024.